Prescient TherapeuticsLtd.
doxorubicin hydrochloride(Prescient Therapeutics, Ltd.)은 Lymphoma 표적 치료제로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). PK: t½ 78.4 days. 차별점: Novel Dipeptidyl Peptidase-4 Inhibitor.
Lymphoma
Male Breast Cancer; Stage II Breast Cancer
Discontinued
Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy
Novel Dipeptidyl Peptidase-4 Inhibitor
target multiple pathway
T cell activation
apoptosis while significantly elevating intracellular reactive oxygen species (ROS), thereby enhancing cytotoxicity
HER2-positive breast cancer models, including cell lines (CD44 high
resistance mechanisms that extend beyond cancer cell intrinsic alterations ultimately reducing therapy efficacy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Prescient TherapeuticsLtd.
doxorubicin hydrochloride(Prescient Therapeutics, Ltd.)은 Lymphoma 표적 치료제로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). PK: t½ 78.4 days. 차별점: Novel Dipeptidyl Peptidase-4 Inhibitor.
Lymphoma
Male Breast Cancer; Stage II Breast Cancer
Discontinued
Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy
Novel Dipeptidyl Peptidase-4 Inhibitor
target multiple pathway
T cell activation
apoptosis while significantly elevating intracellular reactive oxygen species (ROS), thereby enhancing cytotoxicity
HER2-positive breast cancer models, including cell lines (CD44 high
resistance mechanisms that extend beyond cancer cell intrinsic alterations ultimately reducing therapy efficacy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.